Search Results - "Morrow, Monica"

Surgery and prophylactic surgery in hereditary breast cancer by Morrow, Monica

“…Women with hereditary breast cancer are at increased risk of second primary cancers in the ipsilateral and contralateral breast. The level of risk varies with…”
Get full text

MRI for breast cancer screening, diagnosis, and treatment by Morrow, Monica, Prof, Waters, Janet, MLS, Morris, Elizabeth, Prof

“…Summary MRI is used widely both for screening women who are at increased risk of breast cancer and for treatment selection. Prospective studies confirm that…”
Get full text

Will surgery be a part of breast cancer treatment in the future? by Monica Morrow, M D

“…The combination of smaller, screen-detected cancers, improved efficacy of systemic therapy, and increasing use of neoadjuvant therapy with rising rates of…”
Get full text

Overview of Breast Cancer Therapy by Moo, Tracy-Ann, MD, Sanford, Rachel, MD, Dang, Chau, MD, Morrow, Monica, MD

“…Breast cancer treatment is multidisciplinary. Most women with early stage breast cancer are candidates for breast-conserving surgery with radiotherapy or…”
Get full text

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants by Razavi, Pedram, Li, Bob T., Brown, David N., Jung, Byoungsok, Hubbell, Earl, Shen, Ronglai, Abida, Wassim, Juluru, Krishna, De Bruijn, Ino, Hou, Chenlu, Venn, Oliver, Lim, Raymond, Anand, Aseem, Maddala, Tara, Gnerre, Sante, Vijaya Satya, Ravi, Liu, Qinwen, Shen, Ling, Eattock, Nicholas, Yue, Jeanne, Blocker, Alexander W., Lee, Mark, Sehnert, Amy, Xu, Hui, Hall, Megan P., Santiago-Zayas, Angie, Novotny, William F., Isbell, James M., Rusch, Valerie W., Plitas, George, Heerdt, Alexandra S., Ladanyi, Marc, Hyman, David M., Jones, David R., Morrow, Monica, Riely, Gregory J., Scher, Howard I., Rudin, Charles M., Robson, Mark E., Diaz, Luis A., Solit, David B., Aravanis, Alexander M., Reis-Filho, Jorge S.

“…Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological…”
Get full text

Axillary lymph node dissection: Dead or still alive? by Beck, Anna C., Morrow, Monica

“…Although sentinel lymph node biopsy is now the primary method of axillary staging and is therapeutic for patients with limited nodal disease, axillary lymph…”
Get full text

Addressing overtreatment in breast cancer by Katz, Steven J., Morrow, Monica

“…Patients with favorable prognosis of breast cancer are vulnerable to overtreatment because the absolute net benefit of different treatments may be small and…”
Get full text

Clinical Management Factors Contribute to the Decision for Contralateral Prophylactic Mastectomy by KING, Tari A, SAKR, Rita, PATIL, Sujata, GUREVICH, Inga, STEMPEL, Michelle, SAMPSON, Michelle, MORROW, Monica

“…To determine whether increasing rates of contralateral prophylactic mastectomy (CPM) are due to recognition of risk factors for contralateral breast cancer…”
Get full text

Effect of Margin Status on Local Recurrence After Breast Conservation and Radiation Therapy for Ductal Carcinoma In Situ by DUNNE, Clive, BURKE, John P, MORROW, Monica, KELL, Malcolm R

“…There is no consensus on what constitutes an adequate surgical margin in patients receiving breast-conserving surgery (BCS) and postoperative radiation therapy…”
Get full text

Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer by Moran, Meena S., MD, Schnitt, Stuart J., MD, Giuliano, Armando E., MD, Harris, Jay R., MD, Khan, Seema A., MD, Horton, Janet, MD, Klimberg, Suzanne, MD, Chavez-MacGregor, Mariana, MD, Freedman, Gary, MD, Houssami, Nehmat, MD, PhD, Johnson, Peggy L, Morrow, Monica, MD

“…Purpose To convene a multidisciplinary panel of breast experts to examine the relationship between margin width and ipsilateral breast tumor recurrence (IBTR)…”
Get full text

Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer by Iyengar, Neil M, Zhou, Xi Kathy, Gucalp, Ayca, Morris, Patrick G, Howe, Louise R, Giri, Dilip D, Morrow, Monica, Wang, Hanhan, Pollak, Michael, Jones, Lee W, Hudis, Clifford A, Dannenberg, Andrew J

“…Obesity, insulin resistance, and elevated levels of circulating proinflammatory mediators are associated with poorer prognosis in early-stage breast cancer. To…”
Get full text

Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline by VISVANATHAN, Kala, HURLEY, Patricia, GARBER, Judy, KATAPODI, Maria, KRAMER, Barnett, MORROW, Monica, PARKER, Barbara, RUNOWICZ, Carolyn, VOGEL, Victor G, WADE, James L, LIPPMAN, Scott M, BANTUG, Elissa, BROWN, Powel, COL, Nananda F, CUZICK, Jack, DAVIDSON, Nancy E, DECENSI, Andrea, FABIAN, Carol, FORD, Leslie

“…To update the 2009 American Society of Clinical Oncology guideline on pharmacologic interventions for breast cancer (BC) risk reduction. A systematic review of…”
Get full text

Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma? by Pilewskie, Melissa, Stempel, Michelle, Rosenfeld, Hope, Eaton, Anne, Van Zee, Kimberly J., Morrow, Monica

“…Background The Surgery Versus Active Monitoring for Low-Risk DCIS (LORIS) trial is studying the safety of monitoring core-biopsy diagnosed low-risk ductal…”
Get full text

Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk by King, Tari A, Pilewskie, Melissa, Muhsen, Shirin, Patil, Sujata, Mautner, Starr K, Park, Anna, Oskar, Sabine, Guerini-Rocco, Elena, Boafo, Camilla, Gooch, Jessica C, De Brot, Marina, Reis-Filho, Jorge S, Morrogh, Mary, Andrade, Victor P, Sakr, Rita A, Morrow, Monica

“…The increased breast cancer risk conferred by a diagnosis of lobular carcinoma in situ (LCIS) is poorly understood. Here, we review our 29-year longitudinal…”
Get full text

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer by CHANDARLAPATY, Sarat, SAKR, Rita A, KING, Tari A, GIRI, Dilip, PATIL, Sujata, HEGUY, Adriana, MORROW, Monica, MODI, Shanu, NORTON, Larry, ROSEN, Neal, HUDIS, Clifford

“…HER2-amplified breast cancer is sometimes clinically insensitive to HER2-targeted treatment with trastuzumab. Laboratory models of resistance have causally…”
Get full text

The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer by Newman, Lisa A., Reis-Filho, Jorge S., Morrow, Monica, Carey, Lisa A., King, Tari A.

“…Triple-negative breast cancer (TNBC) is an operational term that refers to a heterogeneous collection of breast cancers lacking expression of estrogen receptor…”
Get full text

Postmastectomy Breast Reconstruction: Exploring Plastic Surgeon Practice Patterns and Perspectives by Momoh, Adeyiza O., Griffith, Kent A., Hawley, Sarah T., Morrow, Monica, Ward, Kevin C., Hamilton, Ann S., Shumway, Dean, Katz, Steven J., Jagsi, Reshma

“…Within the multidisciplinary management of breast cancer, variations exist in the reconstructive options offered and care provided. The authors evaluated…”
Get full text

Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision by Kuba, M. Gabriela, Murray, Melissa P., Coffey, Kristen, Calle, Catarina, Morrow, Monica, Brogi, Edi

“…Lobular carcinoma in situ (LCIS) is currently classified as classic (CLCIS), florid (FLCIS), and pleomorphic (PLCIS). Given the rarity of FLCIS and PLCIS,…”
Get full text

MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer by Bitencourt, Almir G.V., Gibbs, Peter, Rossi Saccarelli, Carolina, Daimiel, Isaac, Lo Gullo, Roberto, Fox, Michael J., Thakur, Sunitha, Pinker, Katja, Morris, Elizabeth A., Morrow, Monica, Jochelson, Maxine S.

“…To use clinical and MRI radiomic features coupled with machine learning to assess HER2 expression level and predict pathologic response (pCR) in HER2…”
Get full text

Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women by Subbaramaiah, Kotha, Morris, Patrick G, Zhou, Xi Kathy, Morrow, Monica, Du, Baoheng, Giri, Dilip, Kopelovich, Levy, Hudis, Clifford A, Dannenberg, Andrew J

“…Obesity is a risk factor for hormone receptor-positive breast cancer in postmenopausal women. Estrogen synthesis is catalyzed by aromatase, which is encoded by…”
Get more information